Since the beginning of 2022 CancerAppy has focused on the discovery and development of new therapeutic targets in cancer.
- Has identified CA01 as therapeutic target in triple negative breast.
- Also has identified CA02- CA03, two membrane proteins that are upregulated in NSCLC with K-RAS G12C mutation and has patented their use as targets to vectorize compounds against these tumors, or as surrogates for immune activation, to select patients o explore combinations with new immune therapies.
- Regarding the use of transforming growth factor CA04 as a membrane therapeutic target in pancreatic cancer.
All this thanks to the development of our AI platform in collaboration with our scientific advisors.
Discover, validate and develop Pipeline
Accelerating oncology R&D from target discovery to licensed patents through AI-powered data, workflows, and scientific knowledge at each step.
Current Reseach Projects
Pipeline
Discovery
Preclinical development
Clinical Phase
Target Identification
Target Validation
Early research
Lead up
Late research
IND enable
- CA01 – TNBC
- CA02-03 Lung cancer
- CA04 Pancreatic cancer